DOC2B and neoplasm: To support these, we present evidence to show that (a) inhibition of DOC2B in tumor models leads to more aggressive behavior with the concomitant enhancement in mesenchymal markers expression, and (b) expression or reactivation of DOC2B in tumor cells leads to inhibition of growth, invasion, EMT, and induction of SASP and associated markers.